COMPOUND
A synthetic peptide composed of 16 amino acids.
“Validated for multiple actions related to neurodegenerative diseases,
including cytotoxicity, neuroinflammation, and oxidative stress”
A global leader in innovative drug development
“Validated for multiple actions related to neurodegenerative diseases,
including cytotoxicity, neuroinflammation, and oxidative stress”
Evaluation of medicines in neurodegenerative diseases associated
with abnormal protein aggregation
neurodegenerative diseases associated with abnormal protein aggregation
“Validated for multiple actions related to neurodegenerative diseases,
including cytotoxicity, neuroinflammation, and oxidative stress
Validated for multiple actions related to neurodegenerative diseases”
We are currently conducting a Phase II clinical trial in Korea to evaluate the efficacy and safety of GV1001 in patients with Progressive Supranuclear Palsy (PSP).
Preparations are also underway for a global PSP clinical trial.